Trial · NCT04399538
Results by group280
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 280
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6 | Placebo | -3.58 | 80% Confidence Interval -14.71 to 8.99 | Percent change | |
| Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6 | PF-06865571 25 mg BID + PF-05221304 10 mg BID | -54.07 | 80% Confidence Interval -59.54 to -47.85 | Percent change | |
| Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6 | PF-06865571 100 mg BID + PF-05221304 10 mg BID | -58.14 | 80% Confidence Interval -63.51 to -51.98 | Percent change | |
| Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6 | PF-06865571 300 mg QD + PF-05221304 20 mg QD | -60.28 | 80% Confidence Interval -65.27 to -54.57 | Percent change | |
| Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6 | PF-06865571 300 mg BID + PF-05221304 10 mg BID | -47.75 | 80% Confidence Interval -55.71 to -38.35 | Percent change | |
| Percent CFB in Fasting Serum Triglycerides at Week 6 | Placebo | 3.72 | 80% Confidence Interval -6.90 to 15.55 | Percent change | |
| Percent CFB in Fasting Serum Triglycerides at Week 6 | PF-06865571 25 mg BID + PF-05221304 10 mg BID | 27.89 | 80% Confidence Interval 14.75 to 42.53 | Percent change | |
| Percent CFB in Fasting Serum Triglycerides at Week 6 | PF-06865571 100 mg BID + PF-05221304 10 mg BID | 18.00 | 80% Confidence Interval 5.10 to 32.49 | Percent change | |
| Percent CFB in Fasting Serum Triglycerides at Week 6 | PF-06865571 300 mg QD + PF-05221304 20 mg QD | 24.88 | 80% Confidence Interval 12.85 to 38.20 | Percent change | |
| Percent CFB in Fasting Serum Triglycerides at Week 6 | PF-06865571 300 mg BID + PF-05221304 10 mg BID | 14.69 | 80% Confidence Interval 0.59 to 30.78 | Percent change | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo | All-causality TEAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 25 mg BID + PF-05221304 10 mg BID | All-causality TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 100 mg BID + PF-05221304 10 mg BID | All-causality TEAE | 5 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 300 mg QD + PF-05221304 20 mg QD | All-causality TEAE | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 300 mg BID + PF-05221304 10 mg BID | All-causality TEAE | 7 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo | Treatment-related TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 25 mg BID + PF-05221304 10 mg BID | Treatment-related TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 100 mg BID + PF-05221304 10 mg BID | Treatment-related TEAE | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 300 mg QD + PF-05221304 20 mg QD | Treatment-related TEAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | PF-06865571 300 mg BID + PF-05221304 10 mg BID | Treatment-related TEAE | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04399538/results